AAIC 2026 evidence shows the PrecivityAD2 blood test raised Alzheimer's diagnostic accuracy for people with mild cognitive impairment and dementia to 93% in primary care and 89% in specialty care. Mild cognitive impairment means memory changes beyond normal aging without loss of daily independence, and results changed diagnoses and plans but support testing only with symptoms. The conference met July 12-15, 2026 in London and online, according to the Alzheimer's Association. This guide covers accuracy gains, plan changes, current eligibility, early risk signals, and remaining gaps for MCI decisions.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How accurate was the test in everyday care?
- How did results change diagnoses and care plans?
- Who can use FDA-cleared tests now?
- What does high p-tau217 mean before symptoms?
- What limits and gaps should people with MCI weigh?
How accurate was the test in everyday care?
In a Swedish study of 1,310 patients with mild cognitive impairment or dementia, 165 physicians used PrecivityAD2 alongside evaluation, according to Clinical Lab Products. The test measures amyloid-beta and phosphorylated tau in blood. Primary-care accuracy rose from 65% to 93%, while specialty accuracy rose from 74% to 89%, according to Clinical Lab Products (accuracy gains in primary and specialty care).
For MCI, better accuracy means fewer missed cases and fewer incorrect Alzheimer's labels. Primary care showed the largest gain, which matters for first evaluations. Results still require clinical judgment alongside history, exams, and other tests.
How did results change diagnoses and care plans?
Physicians changed the Alzheimer's diagnosis in about one-third of patients, including 30.0% in primary care, according to BioSpace reporting a C2N-Lund release. They changed planned future care or examinations in 55.9% of cases, according to BioSpace (diagnosis and care-plan changes). The findings applied to symptomatic MCI and dementia care.
A revised diagnosis can change referrals, added scans, or treatment talks. A revised plan can stop unneeded exams or set closer follow-up. Patients and care partners can ask which step changed and why.
Who can use FDA-cleared tests now?
FDA-cleared blood tests remain aids for adults with cognitive symptoms, not general screening, according to NeurologyLive. Lumipulse G was cleared in May 2025 for ages 55 and older, according to NeurologyLive. PrecivityAD2 was cleared August 20, 2026 for ages 40 and older, according to NeurologyLive (FDA clearance details for symptomatic use).
Validation showed 97.6% positive predictive value and 93.1% negative predictive value against PET or spinal-fluid tests, according to NeurologyLive. Positive predictive value means the share of positive results that match PET or spinal-fluid findings. Negative predictive value means the share of negative results that match those findings. Neither test works as a standalone diagnosis, according to NeurologyLive.
- symptoms already present, not routine screening
- age matches the specific test
- physician order as part of full evaluation
What does high p-tau217 mean before symptoms?
Among healthy older adults with very high blood p-tau217, researchers estimated about 78% risk of cognitive impairment over 10 years and about one-in-three risk within five years, according to the Alzheimer's Association (10-year risk estimates for high p-tau217). P-tau217 is a phosphorylated form of tau in blood that tracks Alzheimer's-related change. The results were simultaneously published in JAMA, according to the Alzheimer's Association.
Adults with only slightly elevated p-tau217 still faced 15% risk at five years and 45% at ten years, according to Alzheimer Europe. Researchers said p-tau217 adds prognostic information beyond PET amyloid and genetics, according to Alzheimer Europe. That added signal can help select healthy at-risk volunteers for prevention trials, according to Alzheimer Europe.
What limits and gaps should people with MCI weigh?
The Alzheimer's Association's first 2025 guideline limits recommendations to impaired patients in specialty memory care, according to the Medical Laboratory Observer. Sensitivity means finding true cases, while specificity means correctly ruling out non-cases. Tests reaching at least 90% sensitivity and 90% specificity can substitute for PET or spinal-fluid tests, according to the Medical Laboratory Observer.
Tests reaching at least 90% sensitivity and 75% specificity are triage-only and require confirmation of positives, according to the Medical Laboratory Observer. Many commercial tests vary in accuracy, are not interchangeable, and lack validation across groups and settings, according to the Alzheimer's Association via PR Newswire. Asymptomatic p-tau217 prediction is early and not ready for routine use or doctor-ordered testing without symptoms, according to the Alzheimer's Association.
You Might Also Like
- The AAIC 2026 Swedish Real-World Blood Test Study: Accuracy, Limits, and Evidence Gaps for People With Mild Cognitive Impairment
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: Access, Cost, and Follow-Up Questions for Adults With New Memory Symptoms
- Injection Training for the 2026 At-Home Leqembi Regimen: What the News Means for People With Early Alzheimer’s
